ES2184111T3 - Composiciones para el tratamiento de neuropatias perifericas que contienen antidepresivos y/o inhibidores de la monoaminoxidasa y/o vitamina b12 y/o precursores o inductores de un neurotransmisor. - Google Patents
Composiciones para el tratamiento de neuropatias perifericas que contienen antidepresivos y/o inhibidores de la monoaminoxidasa y/o vitamina b12 y/o precursores o inductores de un neurotransmisor.Info
- Publication number
- ES2184111T3 ES2184111T3 ES97930634T ES97930634T ES2184111T3 ES 2184111 T3 ES2184111 T3 ES 2184111T3 ES 97930634 T ES97930634 T ES 97930634T ES 97930634 T ES97930634 T ES 97930634T ES 2184111 T3 ES2184111 T3 ES 2184111T3
- Authority
- ES
- Spain
- Prior art keywords
- neurotransmitter
- vitamin
- compositions
- treatment
- monoaminoxidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000935 antidepressant agent Substances 0.000 title abstract 2
- 229940005513 antidepressants Drugs 0.000 title abstract 2
- 239000000411 inducer Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002858 neurotransmitter agent Substances 0.000 title abstract 2
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title abstract 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000027232 peripheral nervous system disease Diseases 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 229930003268 Vitamin C Natural products 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
PROCEDIMIENTOS Y COMPOSICIONES PARA EL TRATAMIENTO DE UN PACIENTE QUE PADECE UNA DE LAS DIFERENTES FORMAS DE NEUROPATIA PERIFERICA. ESTE PROCEDIMIENTO COMPRENDE LA ADMINISTRACION AL PACIENTE DE UNA DE LAS COMBINACIONES SIGUIENTES (I) A, B Y C, (II) A Y B, (III) B Y C, (IV) A Y C, EN LAS CUALES A ES UN ANTIDEPRESOR O INHIBIDOR DE MONOAMINA - OXIDASA, B ES LA VITAMINA B 12 , Y C ES UN PRECURSOR O UN INDUCTOR DE UN NEUROTRANSMISOR, POR EJEMPLO LA L -FENIALANINA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9614121.3A GB9614121D0 (en) | 1996-07-05 | 1996-07-05 | Combined medicament |
| GBGB9616019.7A GB9616019D0 (en) | 1996-07-05 | 1996-07-31 | Combined medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2184111T3 true ES2184111T3 (es) | 2003-04-01 |
Family
ID=26309637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97930634T Expired - Lifetime ES2184111T3 (es) | 1996-07-05 | 1997-07-04 | Composiciones para el tratamiento de neuropatias perifericas que contienen antidepresivos y/o inhibidores de la monoaminoxidasa y/o vitamina b12 y/o precursores o inductores de un neurotransmisor. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6335323B2 (es) |
| EP (1) | EP0942751B1 (es) |
| AT (1) | ATE224733T1 (es) |
| AU (1) | AU3451797A (es) |
| CA (1) | CA2259010A1 (es) |
| DE (1) | DE69715899T2 (es) |
| DK (1) | DK0942751T3 (es) |
| ES (1) | ES2184111T3 (es) |
| PT (1) | PT942751E (es) |
| WO (1) | WO1998001157A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197830B1 (en) | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
| GB9617990D0 (en) | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
| US6211171B1 (en) * | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
| GB9904252D0 (en) * | 1999-02-24 | 1999-04-21 | Worsley Andrew P | Composition for the treatment of pain |
| US6575147B2 (en) * | 1999-02-25 | 2003-06-10 | Go-Tec | Internal combustion system adapted for use of a dual fuel composition including acetylene |
| GB9906808D0 (en) * | 1999-03-24 | 1999-05-19 | Kilgowan Limited | Formulation for treatment of pain |
| US6759437B2 (en) | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
| US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
| US20070293571A1 (en) * | 2006-06-08 | 2007-12-20 | Hinz Martin C | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
| EP1490073A4 (en) * | 2002-03-21 | 2006-02-01 | Martin C Hinz | SEGMENT OPTIMIZATION TECHNOLOGY FOR THE SEROTONIN AND CATECHOLAMINE SYSTEM |
| MXPA05008943A (es) * | 2003-02-21 | 2005-11-08 | C Hinz Martin | Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina. |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| JP4638685B2 (ja) * | 2003-06-10 | 2011-02-23 | ハイデルベルガー ドルツクマシーネン アクチエンゲゼルシヤフト | オフセット印刷機による印刷の際に湿し水を調量する方法 |
| GB0313630D0 (en) * | 2003-06-12 | 2003-07-16 | Wwk Trust The | Compositions for the enhanced treatment of depression |
| US20090306050A1 (en) * | 2006-02-03 | 2009-12-10 | Timothy Dinan | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| GB2544630A (en) * | 2015-11-19 | 2017-05-24 | The Wwk Trust | Combinations for the treatment of dementia, and the enhancement of cognitive function |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3981863A (en) * | 1975-02-25 | 1976-09-21 | Micromedic Diagonistics, Inc. | Cyanocobalamin derivatives |
| US4431670A (en) | 1980-12-19 | 1984-02-14 | Bernardo Heller | D-Phenylalanine treatment |
| US4652559A (en) | 1982-08-16 | 1987-03-24 | The Upjohn Company | 2-(Phenylmethylene)cycloalkyl-azetidines |
| CA2200761C (en) * | 1994-10-05 | 2008-02-26 | Cari Loder | Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound |
-
1997
- 1997-07-04 EP EP97930634A patent/EP0942751B1/en not_active Expired - Lifetime
- 1997-07-04 AT AT97930634T patent/ATE224733T1/de not_active IP Right Cessation
- 1997-07-04 CA CA002259010A patent/CA2259010A1/en not_active Abandoned
- 1997-07-04 ES ES97930634T patent/ES2184111T3/es not_active Expired - Lifetime
- 1997-07-04 DE DE69715899T patent/DE69715899T2/de not_active Expired - Fee Related
- 1997-07-04 AU AU34517/97A patent/AU3451797A/en not_active Abandoned
- 1997-07-04 US US09/214,314 patent/US6335323B2/en not_active Expired - Fee Related
- 1997-07-04 PT PT97930634T patent/PT942751E/pt unknown
- 1997-07-04 WO PCT/GB1997/001822 patent/WO1998001157A1/en not_active Ceased
- 1997-07-04 DK DK97930634T patent/DK0942751T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2259010A1 (en) | 1998-01-15 |
| DE69715899T2 (de) | 2003-05-28 |
| EP0942751A1 (en) | 1999-09-22 |
| US6335323B2 (en) | 2002-01-01 |
| ATE224733T1 (de) | 2002-10-15 |
| AU3451797A (en) | 1998-02-02 |
| US20010008884A1 (en) | 2001-07-19 |
| EP0942751B1 (en) | 2002-09-25 |
| DK0942751T3 (da) | 2002-12-02 |
| DE69715899D1 (de) | 2002-10-31 |
| PT942751E (pt) | 2003-02-28 |
| WO1998001157A1 (en) | 1998-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2184111T3 (es) | Composiciones para el tratamiento de neuropatias perifericas que contienen antidepresivos y/o inhibidores de la monoaminoxidasa y/o vitamina b12 y/o precursores o inductores de un neurotransmisor. | |
| EE9400341A (et) | Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon | |
| ATE307119T1 (de) | Bicyclische protein-farnesyl-transferase inhibitoren | |
| BR0312785A (pt) | Tratamento de desordens relacionadas a tnf(alfa) | |
| MX9207449A (es) | Inhibidores de la enzima proteolitica derivada de sacarina. | |
| EA200100934A1 (ru) | Применение ингибиторов cyp2d6 в комбинированных способах лечения | |
| BR9908857A (pt) | Métodos e composições para tratamento, inibição e prevenção de mucosite | |
| DE69528773D1 (de) | Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l-phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung | |
| CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
| DE69831000D1 (de) | Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch | |
| BG100510A (bg) | Метод за лечение на андрогенна алопеция с инхибитори на 5-алфа редуктаза | |
| DE69725860D1 (de) | PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN | |
| ES2136252T3 (es) | Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa. | |
| ES2146249T3 (es) | Composicion farmaceutica para tratar la impotencia que contiene un inhibidor alfa-1 y un inhibidor alfa-2. | |
| ES2168816T3 (es) | Cemento de inyeccion que contiene inhibidores de la corrosion. | |
| DK0876158T3 (da) | Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer | |
| NO20005981L (no) | Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B | |
| EA199901043A1 (ru) | ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА | |
| DK0966283T3 (da) | Farmaceutiske præparater til helbredelse og forebyggelse af sygdomme, som stammer fra beskadigelse af vaskulære endotelceller | |
| DE60231896D1 (de) | Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus | |
| SE9804126D0 (sv) | New pharmaceutical composition | |
| DK0674521T3 (da) | Fremgangsmåde til behandling af kronisk prostatitis med 17beta-N-tertbutylcarbamoyl-4-aza-5a-andost-1-en-3-on | |
| DE60335892D1 (de) | Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung und/oder fettleibigkeit im zusammenhang steht | |
| AR013569A1 (es) | Nueva formulacion mejorada para el tratamiento de la tromboembolia | |
| PA8435601A1 (es) | Composiciones farmaceuticas y metodos de tratamiento de desordenes compulsivos usando inhibidores de naaladasa. |